### Haematuria

Moderatore: Luigi Biancone (Torino)

Presenter: Umberto Maggiore (Parma)

Systematic: Barbara Buscemi (Palermo) - Ilaria Umbro (Roma)

# ERBP 2013

3.5 On which criteria should we select living kidney donors to optimize the risk-benefit ratio of their donation?

#### <u>Haematuria</u>

- We recommend considering persistent haematuria of glomerular origin as a contraindication to living donation, because it may indicate kidney disease in the donor. (1B)

- However, we acknowledge thin basement membrane disease might be an exception. (Ungraded statement)

# **KDIGO 2015**

### CHAPTER 7: EVALUATION OF HEMATURIA AND INDICATIONS FOR KIDNEY BIOPSY IN KIDNEY DONOR CANDIDATES

#### **Evaluation**

- 7.1: All donor candidates should be screened for the presence of microscopic hematuria. (Not Graded)
- 7.2: Donor candidates with persistent microscopic hematuria should undergo testing to identify possible underlying causes which may include (potential tests in parentheses): (Not Graded)
  - Infection (urinalysis and urine culture)
  - Nephrolithiasis/microlithiasis (urography and a 24-hr urine stone panel)
  - Malignancy (multiphasic computerized tomography, or urography with and without IV contrast, or magnetic resonance urography AND cystoscopy, along with a focused history evaluating demographic and clinical cancer risk factors)
  - Glomerular disease (measurement of GFR, urinary protein, focused review of family history of kidney disease, and consideration of renal biopsy)

### **KDIGO 2015**

### CHAPTER 7: EVALUATION OF HEMATURIA AND INDICATIONS FOR KIDNEY BIOPSY IN KIDNEY DONOR CANDIDATES

#### **Donor Selection**

- 7.3: Hematuria from a reversible cause, such as infection, that resolves with treatment is not a contraindication to kidney donation. (Not Graded)
- 7.4: Some donor candidates with microscopic hematuria also have other characteristics which associate with a higher lifetime risk of ESRD (such as a low GFR, high levels of albuminuria, hypertension, or evidence of a glomerular disease on kidney biopsy such as IgA nephropathy). Such donor candidates should generally be excluded from kidney donation. (Not Graded)



#### The Role of Kidney Biopsy to Determine Donation from Prospective Kidney Donors with Asymptomatic Urinary Abnormalities

S.R. Choi, I.O. Sun, Y.A. Hong, H.G. Kim, H.S. Park, B.H. Chung, B.S. Choi, C.W. Park, Y.S. Kim, and C.W. Yang

Transplantation Proceedings, 44, 11–13 (2012)

- 15 prospective kidney donors who underwent a kidney biopsy from January 1996 to December 2010. The results of the kidney biopsy indicated the presence of asymptomatic persistent microscopic hematuria (n 14; 93.3%) or borderline proteinuria (n 1; 6.7%)
- Results:
  - thin basement membrane nephropathy (TBMN) (n 7; 50%)
  - mild mesangiopathy (n 3; 22%)
  - immunoglobulin A nephropathy (IgAN; n 2; 14%),
  - focal segmental glomerulosclerosis (FSGS) (n 1; 7%)
  - nonspecific interstitial changes (n 1; 7%)
  - In addition, the prospective donor with borderline proteinuria revealed glomerulosclerosis (26%) and arteriosclerosis
- Of the 14 candidate donors with persistent microscopic hematuria, 9 were accepted as kidney donors (5 with TBMN, 3 with mild mesangiopathy, 1 with nonspecific interstitial changes)
- 5 potential donors with persistent microscopic hematuria and 1 candidate donor with borderline proteinuria were excluded from donation owing to IgAN (n 2; 33%), TBMN (n 2; 33%), FSGS (n 1; 17%), and arteriosclerosis (n 1; 17%)
- The function of the 9 allografts was relatively stable during the follow-up with the exception of 2 cases: 1 recipient experienced graft failure due to acute rejection, and 1 with a functioning graft died due to cardiac arrest
- Over a mean follow-up of 56.9 months, we observed the mean eGFR at 1 year after transplantation and the current eGFR to be 57.1 ± 17.3 and 47.7 ± 30.8 mL/min/1.73 m2, respectively

### Practice Patterns in Evaluation of Living Kidney Donors in United Network for Organ Sharing-Approved Kidney Transplant Centers

Amarpali Brar<sup>a</sup> Rahul M. Jindal<sup>b</sup> Moro O. Salifu<sup>a</sup> Kevin C. Abbott<sup>b</sup> Fr

Frank P. Hurst<sup>b</sup> Am J Nephrol 2012;35:466–473 DOI: <u>10.1159/000338450</u>

- Hematuria was defined as > 5 cells/HPF (43.3%), > 3 cells/HPF (26.9%), > 2/HPF (17.9%) and positive dipstick (22.4%)
- Donors with hematuria were accepted by 38.8% of the centers
- Renal biopsy to exclude glomerular cause of hematuria was performed by 58.2%, whereas only 22.7% used the currently available genetic tests
- Centers which accepted donors with hematuria required patients to have normal cystoscopy, imaging and kidney biopsy

**Fig. 4.** Criteria for inclusion of potential living donors with hematuria.

37-question electronic survey to gather information about living kidney donor evaluation and selection processes. Based on self-reporting that may not accurately represent actual practice of centers

